Adult Dosing
Acute Lymphocytic Leukemia, Lymphomas, Rhabdomyosarcoma, Neuroblastoma, Wilms Tumor
- 1.4 mg/m2 IV qwk
- Max: 2 mg/dose
- Note: Adjust dose based on clinical response and toxicity
Pediatric Dosing
Acute Lymphocytic Leukemia, Lymphomas, Rhabdomyosarcoma, Neuroblastoma, Wilms Tumor
Child 
10 kgs
- 0.05 mg/kg IV qwk
- Max: 2 mg/dose
Child > 10 kgs
- 1.5-2 mg/m2 IV qwk
- Note: adjust dose based on clinical response and toxicity
[Outline]
- Extreme care must be used in calculating and administering vincristine dose. overdosage may result in serious or fatal outcome
- Rare cases of allergic reactions such as anaphylaxis, rash and edema have been reported in patients receiving vincristine as a part of multidrug chemotherapy regimens
- Acute uric acid nephropathy has also been reported with vincristine sulfate. In the presence of leukopenia or a complicating infection, administer next dose after careful consideration
- Acute shortness of breath and severe bronchospasm may occur if the drug is used with mitomycin-C
- Vincristine does not cross blood brain barrier in sufficient amounts. Additional agents may be required in central nervous system leukemia
- Monitor bilirubin at baseline; CBC with differential count prior to each dose
- Monitor serum uric acid frequently during 1st 3-4wk of therapy if acute leukemia
- Monitor for neurotoxicity and life-threatening bronchospasm; neurotoxicity is dose-related and usually reversible
Cautions: Use cautiously in
- Hepatic impairment
- Pulmonary disease
- Myelosuppression
- Neuropathy
- Neuromuscular disease
- Concurrent neurotoxic agents
- Concurrent ototoxic agents
Pregnancy Category:D
Breastfeeding: Cancer chemotherapy drugs may interfere with cellular metabolism of the nursing infant. Most sources consider breastfeeding to be contraindicated with antineoplastic therapy. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 May 2010).
